Annovis Bio Inc. (NYSE: ANVS) has named Hui Liu as its new Director of Biostatistics, a move aimed at bolstering the company's scientific research capabilities in neurodegenerative disease treatment. Liu brings nearly two decades of experience in clinical trial design, analysis, and regulatory submission support across multiple therapeutic areas.
The appointment comes as Annovis Bio advances its critical Phase 3 Alzheimer's disease trial. Liu's expertise is expected to significantly reinforce the scientific integrity of the company's research data and improve regulatory strategies for developing transformative therapies targeting neurodegenerative disorders.
With over 19 years of professional experience, Liu will play a crucial role in analyzing and interpreting complex clinical trial data. Her expertise is particularly valuable as Annovis Bio continues its mission of developing innovative treatments that target multiple neurotoxic proteins with the ultimate goal of restoring brain function and improving patient quality of life.
The addition of Liu to the research team represents a strategic enhancement of Annovis Bio's scientific capabilities. Her deep understanding of biostatistics and clinical trial methodologies will be instrumental in advancing the company's research objectives and potentially bringing breakthrough treatments to patients suffering from Alzheimer's and other neurodegenerative conditions.
